Indicators
Indicators
Value
Direction
MACD(12,26,9)
-3.457
Sell
RSI(14)
35.145
Neutral
STOCH(KDJ)(9,3,3)
39.468
Neutral
ATR(14)
4.450
Low Volatility
CCI(14)
-92.952
Neutral
Williams %R
68.233
Sell
TRIX(12,20)
-0.278
Sell
StochRSI(14)
93.505
Buy
Disc Medicine Inc
IRON80.330USD
-0.100-0.12%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
2.81BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Disc Medicine Inc
Currency: USD Updated: 2025-10-27Key Insights
Its valuation is considered undervalued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at max_target_price.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Disc Medicine Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
13
analysts
Buy
Current Rating
118.917
Target Price
+28.92%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Disc Medicine Inc Highlights
StrengthsRisks
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -20.09, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 34.67M shares, decreasing 8.78% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 6.08K shares of this stock.
Financial Health
Currency: USD Updated: 2025-10-27No financial score is currently available for Disc Medicine Inc. The Biotechnology & Medical Research industry's average is 6.92.
Score
Financials
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
Operational Efficiency
Growth Potential
Shareholder Returns
Disc Medicine Inc's Company Valuation
Currency: USD Updated: 2025-10-27The current valuation score of Disc Medicine Inc is 6.82, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry. Its current P/E ratio is -20.09, which is -56.23% below the recent high of -8.79 and -0.32% above the recent low of -20.16.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 181/501
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-10-27The current earnings forecast score of Disc Medicine Inc is 8.67, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry. The average price target for Disc Medicine Inc is 110.00, with a high of 153.00 and a low of 85.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
118.917
Target Price
+28.92%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
534
Total
6
Median
6
Average
Company name
Ratings
Analysts
Disc Medicine Inc
IRON
13
CRISPR Therapeutics AG
CRSP
30
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-10-27The current price momentum score of Disc Medicine Inc is 9.41, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 102.10 and the support level at 71.04, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
80.032
Buy
MA10
85.341
Sell
MA20
88.901
Sell
MA50
88.049
Sell
MA100
75.370
Buy
MA200
62.864
Buy
Institutional Confidence
Currency: USD Updated: 2025-10-27The current institutional shareholding score of Disc Medicine Inc is 10.00, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 99.74%, representing a quarter-over-quarter decrease of 7.50%. The largest institutional shareholder is PRFDX, holding a total of 1.49M shares, representing 4.30% of shares outstanding, with 7.02% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Fidelity Management & Research Company LLC
Access Industries, Inc.
BlackRock Institutional Trust Company, N.A.
RA Capital Management, LP
Atlas Venture
Frazier Life Sciences Management, L.P.
OrbiMed Advisors, LLC
Wellington Management Company, LLP
1
2
Risk Assessment
Currency: USD Updated: 2025-10-27No risk assessment score is currently available for Disc Medicine Inc. The Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 0.76. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.85
VaR
+6.02%
240-Day Maximum Drawdown
+43.36%
240-Day Volatility
+62.79%
Return
Best Daily Return
60 days
+20.95%
120 days
+20.95%
5 years
+47.33%
Worst Daily Return
60 days
-11.50%
120 days
-11.50%
5 years
-45.05%
Sharpe Ratio
60 days
+1.64
120 days
+2.04
5 years
+0.14
Risk Assessment
Maximum Drawdown
240 days
+43.36%
3 years
+64.79%
5 years
+93.08%
Return-to-Drawdown Ratio
240 days
+0.85
3 years
+1.19
5 years
-0.12
Skewness
240 days
+0.58
3 years
-1.49
5 years
+0.47
Volatility
Realised Volatility
240 days
+62.79%
5 years
+93.21%
Standardised True Range
240 days
+3.64%
5 years
+3.64%
Downside Risk-Adjusted Return
120 days
+340.88%
240 days
+340.88%
Maximum Daily Upside Volatility
60 days
+61.28%
Maximum Daily Downside Volatility
60 days
+54.59%
Liquidity
Average Turnover Rate
60 days
+1.04%
120 days
+1.17%
5 years
--
Turnover Deviation
20 days
-25.57%
60 days
-13.58%
120 days
-2.38%
Peer Comparison
Biotechnology & Medical Research
Disc Medicine Inc
IRON
5.64 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.82 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Dynavax Technologies Corp
DVAX
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Disc Medicine Inc?
The TradingKey Stock Score provides a comprehensive assessment of Disc Medicine Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Disc Medicine Inc’s performance and outlook.
How do we generate the financial health score of Disc Medicine Inc?
To generate the financial health score of Disc Medicine Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Disc Medicine Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Disc Medicine Inc.
How do we generate the company valuation score of Disc Medicine Inc?
To generate the company valuation score of Disc Medicine Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Disc Medicine Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Disc Medicine Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Disc Medicine Inc.
How do we generate the earnings forecast score of Disc Medicine Inc?
To calculate the earnings forecast score of Disc Medicine Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Disc Medicine Inc’s future.
How do we generate the price momentum score of Disc Medicine Inc?
When generating the price momentum score for Disc Medicine Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Disc Medicine Inc’s prices. A higher score indicates a more stable short-term price trend for Disc Medicine Inc.
How do we generate the institutional confidence score of Disc Medicine Inc?
To generate the institutional confidence score of Disc Medicine Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Disc Medicine Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Disc Medicine Inc.
How do we generate the risk management score of Disc Medicine Inc?
To assess the risk management score of Disc Medicine Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Disc Medicine Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Disc Medicine Inc.
